Ticker
AGTC

Price
0.43
Stock movement up
+0.02 (4.07%)
Company name
Applied Genetic
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
28.85M
Ent value
1.17M
Price/Sales
57.71
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-87.90%
3 year return
-45.72%
5 year return
-37.69%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AGTC does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales57.71
Price to Book-
EV to Sales2.34

FINANCIALS

Per share

Loading...
Per share data
Current share count66.81M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)500.00K
Gross profit (TTM)0.00
Operating income (TTM)-48.65M
Net income (TTM)-48.40M
EPS (TTM)-
EPS (1y forward)-1.13

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-9730.80%
Profit margin (TTM)-9679.80%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash67.85M
Net receivables0.00
Total current assets70.53M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets87.19M
Accounts payable3.56M
Short/Current long term debt24.56M
Total current liabilities25.81M
Total liabilities40.16M
Shareholder's equity0.00
Net tangible assets45.65M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-60.92M
Capital expenditures (TTM)2.03M
Free cash flow (TTM)-62.95M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.42
Daily high0.43
Daily low0.42
Daily Volume461K
All-time high31.69
1y analyst estimate10.00
Beta1.67
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date21 Sep 2022

Downside potential

Loading...
Downside potential data
AGTCS&P500
Current price drop from All-time high-98.64%-12.18%
Highest price drop-98.88%-56.47%
Date of highest drop15 Jul 20229 Mar 2009
Avg drop from high-73.06%-11.38%
Avg time to new high151 days12 days
Max time to new high2063 days1805 days
COMPANY DETAILS
AGTC (Applied Genetic) company logo
Marketcap
28.85M
Marketcap category
Small-cap
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
Employees
83
Investor relations
-
SEC filings
CEO
Susan B. Washer
Country
USA
City
Alachua
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company fo...
September 1, 2022
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the late-stage development and potential commercialization of AGTC’s X-Linked Re...
July 26, 2022
Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I t...
July 24, 2022
GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company foc...
July 13, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focu...
July 12, 2022
July 7, 2022 at 8:00 AM EDTGAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company fo...
July 7, 2022
AGTC Welcomes Eduardo Jacobo as the Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as the Sr. Vice President of Clinical Research and Medical AffairsGAINESVILLE, Fla. and CAMBRIDGE, Mass...
June 8, 2022
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of...
June 6, 2022
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of...
June 1, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of a...
May 18, 2022
Next page